Biohaven .(US:BHVN) GlobeNewswire News Roomยท2025-07-16 15:39Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Biohaven Ltd. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's drug candidates and their regulatory prospects [3][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $50,000 in Biohaven between March 24, 2023, and May 14, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Biohaven, with a deadline of September 12, 2025, for investors to seek the role of lead plaintiff [3][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Biohaven - The complaint alleges that Biohaven and its executives made false or misleading statements regarding the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [5]. - It is claimed that the overstated regulatory prospects and clinical data could significantly negatively impact Biohaven's business and financial condition once revealed [5]. Group 3: Stock Price Impact - Following a press release on May 14, 2025, regarding the extension of the PDUFA date for troriluzole, Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share on May 15, 2025 [6].